Global Rheumatology Therapeutics
Global Rheumatology Therapeutics

Rheumatology Therapeutics Comprehensive Study by Type (Disease Modifying Anti-rheumatic Drugs (DMARDs), Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids, Uric Acid Drugs), Distribution Chanel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Route of Administration (Parenteral Route, Oral Route, Topical), Disease (Rheumatoid Arthritis, Osteoarthritis, Gout, Psoriatic Arthritis, Ankylosing Spondylitis, Other) Players and Region - Global Market Outlook to 2024

Rheumatology Therapeutics Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

Jun 2019 Edition 243 Pages 220 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Scope of the Study
The rheumatology devoted to adequate diagnosis and therapy of rheumatic diseases including clinical problems in joints, soft tissues, heritable connective tissue disorders, vasculitis and autoimmune diseases. Rheumatology therapeutic is a treatment of rheumatic diseases. The rheumatology diseases generally affect the supporting and connecting structures and bones like muscles, ligaments, joints etc. Rheumatology Therapeutics market revenue was xx.xx Million USD in 2014, grew to xx.xx Million USD in 2019, and will reach xx.xx Million USD in 2024, with a CAGR of x.x% during 2019-2024.

The market study is being classified by Type (Disease Modifying Anti-rheumatic Drugs (DMARDs), Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids and Uric Acid Drugs) and major geographies with country level break-up.

AbbVie, Inc. (United States), Bristol-Myers Squibb Company (United States), Pfizer (United States), Merck & Co., Inc. (United States), Amgen, Inc. (United States), Novartis AG (Switzerland), Janssen Biotech, Inc. (United States), Sanofi (France), Genentech, Inc. (United States) and Takeda Pharmaceutical (Japan) are some of the key players profiled in the study.

Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Rheumatology Therapeutics market throughout the predicted period.

Segment Analysis
AdvanceMarketAnalytics has segmented the market of Global Rheumatology Therapeutics market by Type, Application and Region.

On the basis of geography, the market of Rheumatology Therapeutics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Distribution Chanel, the sub-segment i.e. Hospital Pharmacy will boost the Rheumatology Therapeutics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Route of Administration, the sub-segment i.e. Parenteral Route will boost the Rheumatology Therapeutics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Disease, the sub-segment i.e. Rheumatoid Arthritis will boost the Rheumatology Therapeutics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increasing Population with Rheumatology Arthritis Worldwide
  • Increase in the Number of New Drugs Approved

Market Trend
  • Demand for Drugs with Improved Quality

Restraints
  • Patent Expiration of the Some Drugs
  • Lack of Awareness about Treatment among Developing Countries

Opportunities
  • Growing Geriatric Population Worldwide
  • Rising Demand for Biosimilar Products

Challenges
  • High Research and Development Cost


On 19th February 2019, AbbVie, Inc., a research-based global biopharmaceutical company, announced that United States Food and Drug Administration (FDA) accepted for priority review its New Drug Application (NDA) for upadacitinib for the treatment of adult patients with moderate to severe rheumatoid arthritis.


Key Target Audience
Rheumatology Therapeutic Drugs Manufacturers, Raw Material Suppliers/ Buyers, Distributors, Research Organization and Associations, Government Body & Associations and End-user

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Disease Modifying Anti-rheumatic Drugs (DMARDs)
  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  • Corticosteroids
  • Uric Acid Drugs
By Distribution Chanel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Route of Administration
  • Parenteral Route
  • Oral Route
  • Topical

By Disease
  • Rheumatoid Arthritis
  • Osteoarthritis
  • Gout
  • Psoriatic Arthritis
  • Ankylosing Spondylitis
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Population with Rheumatology Arthritis Worldwide
      • 3.2.2. Increase in the Number of New Drugs Approved
    • 3.3. Market Challenges
      • 3.3.1. High Research and Development Cost
    • 3.4. Market Trends
      • 3.4.1. Demand for Drugs with Improved Quality
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Rheumatology Therapeutics, by Type, Distribution Chanel, Route of Administration, Disease and Region (value, volume and price ) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Rheumatology Therapeutics (Value)
      • 5.2.1. Global Rheumatology Therapeutics by: Type (Value)
        • 5.2.1.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
        • 5.2.1.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        • 5.2.1.3. Corticosteroids
        • 5.2.1.4. Uric Acid Drugs
      • 5.2.2. Global Rheumatology Therapeutics by: Distribution Chanel (Value)
        • 5.2.2.1. Hospital Pharmacy
        • 5.2.2.2. Retail Pharmacy
        • 5.2.2.3. Online Pharmacy
      • 5.2.3. Global Rheumatology Therapeutics by: Route of Administration (Value)
        • 5.2.3.1. Parenteral Route
        • 5.2.3.2. Oral Route
        • 5.2.3.3. Topical
      • 5.2.4. Global Rheumatology Therapeutics by: Disease (Value)
        • 5.2.4.1. Rheumatoid Arthritis
        • 5.2.4.2. Osteoarthritis
        • 5.2.4.3. Gout
        • 5.2.4.4. Psoriatic Arthritis
        • 5.2.4.5. Ankylosing Spondylitis
        • 5.2.4.6. Other
      • 5.2.5. Global Rheumatology Therapeutics Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Rheumatology Therapeutics (Volume)
      • 5.3.1. Global Rheumatology Therapeutics by: Type (Volume)
        • 5.3.1.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
        • 5.3.1.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        • 5.3.1.3. Corticosteroids
        • 5.3.1.4. Uric Acid Drugs
      • 5.3.2. Global Rheumatology Therapeutics by: Distribution Chanel (Volume)
        • 5.3.2.1. Hospital Pharmacy
        • 5.3.2.2. Retail Pharmacy
        • 5.3.2.3. Online Pharmacy
      • 5.3.3. Global Rheumatology Therapeutics by: Route of Administration (Volume)
        • 5.3.3.1. Parenteral Route
        • 5.3.3.2. Oral Route
        • 5.3.3.3. Topical
      • 5.3.4. Global Rheumatology Therapeutics by: Disease (Volume)
        • 5.3.4.1. Rheumatoid Arthritis
        • 5.3.4.2. Osteoarthritis
        • 5.3.4.3. Gout
        • 5.3.4.4. Psoriatic Arthritis
        • 5.3.4.5. Ankylosing Spondylitis
        • 5.3.4.6. Other
      • 5.3.5. Global Rheumatology Therapeutics Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Rheumatology Therapeutics (Price)
      • 5.4.1. Global Rheumatology Therapeutics by: Type (Price)
  • 6. Rheumatology Therapeutics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AbbVie, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bristol-Myers Squibb Company (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pfizer (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Merck & Co., Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Amgen, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Novartis AG (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Janssen Biotech, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sanofi (France)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Genentech, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Takeda Pharmaceutical (Japan)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Rheumatology Therapeutics Sale, by Type, Distribution Chanel, Route of Administration, Disease and Region (value, volume and price ) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Rheumatology Therapeutics (Value)
      • 7.2.1. Global Rheumatology Therapeutics by: Type (Value)
        • 7.2.1.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
        • 7.2.1.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        • 7.2.1.3. Corticosteroids
        • 7.2.1.4. Uric Acid Drugs
      • 7.2.2. Global Rheumatology Therapeutics by: Distribution Chanel (Value)
        • 7.2.2.1. Hospital Pharmacy
        • 7.2.2.2. Retail Pharmacy
        • 7.2.2.3. Online Pharmacy
      • 7.2.3. Global Rheumatology Therapeutics by: Route of Administration (Value)
        • 7.2.3.1. Parenteral Route
        • 7.2.3.2. Oral Route
        • 7.2.3.3. Topical
      • 7.2.4. Global Rheumatology Therapeutics by: Disease (Value)
        • 7.2.4.1. Rheumatoid Arthritis
        • 7.2.4.2. Osteoarthritis
        • 7.2.4.3. Gout
        • 7.2.4.4. Psoriatic Arthritis
        • 7.2.4.5. Ankylosing Spondylitis
        • 7.2.4.6. Other
      • 7.2.5. Global Rheumatology Therapeutics Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Rheumatology Therapeutics (Volume)
      • 7.3.1. Global Rheumatology Therapeutics by: Type (Volume)
        • 7.3.1.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
        • 7.3.1.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        • 7.3.1.3. Corticosteroids
        • 7.3.1.4. Uric Acid Drugs
      • 7.3.2. Global Rheumatology Therapeutics by: Distribution Chanel (Volume)
        • 7.3.2.1. Hospital Pharmacy
        • 7.3.2.2. Retail Pharmacy
        • 7.3.2.3. Online Pharmacy
      • 7.3.3. Global Rheumatology Therapeutics by: Route of Administration (Volume)
        • 7.3.3.1. Parenteral Route
        • 7.3.3.2. Oral Route
        • 7.3.3.3. Topical
      • 7.3.4. Global Rheumatology Therapeutics by: Disease (Volume)
        • 7.3.4.1. Rheumatoid Arthritis
        • 7.3.4.2. Osteoarthritis
        • 7.3.4.3. Gout
        • 7.3.4.4. Psoriatic Arthritis
        • 7.3.4.5. Ankylosing Spondylitis
        • 7.3.4.6. Other
      • 7.3.5. Global Rheumatology Therapeutics Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Rheumatology Therapeutics (Price)
      • 7.4.1. Global Rheumatology Therapeutics by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Rheumatology Therapeutics: by Type(USD Million)
  • Table 2. Rheumatology Therapeutics Disease Modifying Anti-rheumatic Drugs (DMARDs) , by Region USD Million (2013-2018)
  • Table 3. Rheumatology Therapeutics Nonsteroidal Anti-inflammatory Drugs (NSAIDs) , by Region USD Million (2013-2018)
  • Table 4. Rheumatology Therapeutics Corticosteroids , by Region USD Million (2013-2018)
  • Table 5. Rheumatology Therapeutics Uric Acid Drugs , by Region USD Million (2013-2018)
  • Table 6. Rheumatology Therapeutics: by Distribution Chanel(USD Million)
  • Table 7. Rheumatology Therapeutics Hospital Pharmacy , by Region USD Million (2013-2018)
  • Table 8. Rheumatology Therapeutics Retail Pharmacy , by Region USD Million (2013-2018)
  • Table 9. Rheumatology Therapeutics Online Pharmacy , by Region USD Million (2013-2018)
  • Table 10. Rheumatology Therapeutics: by Route of Administration(USD Million)
  • Table 11. Rheumatology Therapeutics Parenteral Route , by Region USD Million (2013-2018)
  • Table 12. Rheumatology Therapeutics Oral Route , by Region USD Million (2013-2018)
  • Table 13. Rheumatology Therapeutics Topical , by Region USD Million (2013-2018)
  • Table 14. Rheumatology Therapeutics: by Disease(USD Million)
  • Table 15. Rheumatology Therapeutics Rheumatoid Arthritis , by Region USD Million (2013-2018)
  • Table 16. Rheumatology Therapeutics Osteoarthritis , by Region USD Million (2013-2018)
  • Table 17. Rheumatology Therapeutics Gout , by Region USD Million (2013-2018)
  • Table 18. Rheumatology Therapeutics Psoriatic Arthritis , by Region USD Million (2013-2018)
  • Table 19. Rheumatology Therapeutics Ankylosing Spondylitis , by Region USD Million (2013-2018)
  • Table 20. Rheumatology Therapeutics Other , by Region USD Million (2013-2018)
  • Table 21. South America Rheumatology Therapeutics, by Country USD Million (2013-2018)
  • Table 22. South America Rheumatology Therapeutics, by Type USD Million (2013-2018)
  • Table 23. South America Rheumatology Therapeutics, by Distribution Chanel USD Million (2013-2018)
  • Table 24. South America Rheumatology Therapeutics, by Route of Administration USD Million (2013-2018)
  • Table 25. South America Rheumatology Therapeutics, by Disease USD Million (2013-2018)
  • Table 26. Brazil Rheumatology Therapeutics, by Type USD Million (2013-2018)
  • Table 27. Brazil Rheumatology Therapeutics, by Distribution Chanel USD Million (2013-2018)
  • Table 28. Brazil Rheumatology Therapeutics, by Route of Administration USD Million (2013-2018)
  • Table 29. Brazil Rheumatology Therapeutics, by Disease USD Million (2013-2018)
  • Table 30. Argentina Rheumatology Therapeutics, by Type USD Million (2013-2018)
  • Table 31. Argentina Rheumatology Therapeutics, by Distribution Chanel USD Million (2013-2018)
  • Table 32. Argentina Rheumatology Therapeutics, by Route of Administration USD Million (2013-2018)
  • Table 33. Argentina Rheumatology Therapeutics, by Disease USD Million (2013-2018)
  • Table 34. Rest of South America Rheumatology Therapeutics, by Type USD Million (2013-2018)
  • Table 35. Rest of South America Rheumatology Therapeutics, by Distribution Chanel USD Million (2013-2018)
  • Table 36. Rest of South America Rheumatology Therapeutics, by Route of Administration USD Million (2013-2018)
  • Table 37. Rest of South America Rheumatology Therapeutics, by Disease USD Million (2013-2018)
  • Table 38. Asia Pacific Rheumatology Therapeutics, by Country USD Million (2013-2018)
  • Table 39. Asia Pacific Rheumatology Therapeutics, by Type USD Million (2013-2018)
  • Table 40. Asia Pacific Rheumatology Therapeutics, by Distribution Chanel USD Million (2013-2018)
  • Table 41. Asia Pacific Rheumatology Therapeutics, by Route of Administration USD Million (2013-2018)
  • Table 42. Asia Pacific Rheumatology Therapeutics, by Disease USD Million (2013-2018)
  • Table 43. China Rheumatology Therapeutics, by Type USD Million (2013-2018)
  • Table 44. China Rheumatology Therapeutics, by Distribution Chanel USD Million (2013-2018)
  • Table 45. China Rheumatology Therapeutics, by Route of Administration USD Million (2013-2018)
  • Table 46. China Rheumatology Therapeutics, by Disease USD Million (2013-2018)
  • Table 47. Japan Rheumatology Therapeutics, by Type USD Million (2013-2018)
  • Table 48. Japan Rheumatology Therapeutics, by Distribution Chanel USD Million (2013-2018)
  • Table 49. Japan Rheumatology Therapeutics, by Route of Administration USD Million (2013-2018)
  • Table 50. Japan Rheumatology Therapeutics, by Disease USD Million (2013-2018)
  • Table 51. India Rheumatology Therapeutics, by Type USD Million (2013-2018)
  • Table 52. India Rheumatology Therapeutics, by Distribution Chanel USD Million (2013-2018)
  • Table 53. India Rheumatology Therapeutics, by Route of Administration USD Million (2013-2018)
  • Table 54. India Rheumatology Therapeutics, by Disease USD Million (2013-2018)
  • Table 55. South Korea Rheumatology Therapeutics, by Type USD Million (2013-2018)
  • Table 56. South Korea Rheumatology Therapeutics, by Distribution Chanel USD Million (2013-2018)
  • Table 57. South Korea Rheumatology Therapeutics, by Route of Administration USD Million (2013-2018)
  • Table 58. South Korea Rheumatology Therapeutics, by Disease USD Million (2013-2018)
  • Table 59. Taiwan Rheumatology Therapeutics, by Type USD Million (2013-2018)
  • Table 60. Taiwan Rheumatology Therapeutics, by Distribution Chanel USD Million (2013-2018)
  • Table 61. Taiwan Rheumatology Therapeutics, by Route of Administration USD Million (2013-2018)
  • Table 62. Taiwan Rheumatology Therapeutics, by Disease USD Million (2013-2018)
  • Table 63. Australia Rheumatology Therapeutics, by Type USD Million (2013-2018)
  • Table 64. Australia Rheumatology Therapeutics, by Distribution Chanel USD Million (2013-2018)
  • Table 65. Australia Rheumatology Therapeutics, by Route of Administration USD Million (2013-2018)
  • Table 66. Australia Rheumatology Therapeutics, by Disease USD Million (2013-2018)
  • Table 67. Rest of Asia-Pacific Rheumatology Therapeutics, by Type USD Million (2013-2018)
  • Table 68. Rest of Asia-Pacific Rheumatology Therapeutics, by Distribution Chanel USD Million (2013-2018)
  • Table 69. Rest of Asia-Pacific Rheumatology Therapeutics, by Route of Administration USD Million (2013-2018)
  • Table 70. Rest of Asia-Pacific Rheumatology Therapeutics, by Disease USD Million (2013-2018)
  • Table 71. Europe Rheumatology Therapeutics, by Country USD Million (2013-2018)
  • Table 72. Europe Rheumatology Therapeutics, by Type USD Million (2013-2018)
  • Table 73. Europe Rheumatology Therapeutics, by Distribution Chanel USD Million (2013-2018)
  • Table 74. Europe Rheumatology Therapeutics, by Route of Administration USD Million (2013-2018)
  • Table 75. Europe Rheumatology Therapeutics, by Disease USD Million (2013-2018)
  • Table 76. Germany Rheumatology Therapeutics, by Type USD Million (2013-2018)
  • Table 77. Germany Rheumatology Therapeutics, by Distribution Chanel USD Million (2013-2018)
  • Table 78. Germany Rheumatology Therapeutics, by Route of Administration USD Million (2013-2018)
  • Table 79. Germany Rheumatology Therapeutics, by Disease USD Million (2013-2018)
  • Table 80. France Rheumatology Therapeutics, by Type USD Million (2013-2018)
  • Table 81. France Rheumatology Therapeutics, by Distribution Chanel USD Million (2013-2018)
  • Table 82. France Rheumatology Therapeutics, by Route of Administration USD Million (2013-2018)
  • Table 83. France Rheumatology Therapeutics, by Disease USD Million (2013-2018)
  • Table 84. Italy Rheumatology Therapeutics, by Type USD Million (2013-2018)
  • Table 85. Italy Rheumatology Therapeutics, by Distribution Chanel USD Million (2013-2018)
  • Table 86. Italy Rheumatology Therapeutics, by Route of Administration USD Million (2013-2018)
  • Table 87. Italy Rheumatology Therapeutics, by Disease USD Million (2013-2018)
  • Table 88. United Kingdom Rheumatology Therapeutics, by Type USD Million (2013-2018)
  • Table 89. United Kingdom Rheumatology Therapeutics, by Distribution Chanel USD Million (2013-2018)
  • Table 90. United Kingdom Rheumatology Therapeutics, by Route of Administration USD Million (2013-2018)
  • Table 91. United Kingdom Rheumatology Therapeutics, by Disease USD Million (2013-2018)
  • Table 92. Netherlands Rheumatology Therapeutics, by Type USD Million (2013-2018)
  • Table 93. Netherlands Rheumatology Therapeutics, by Distribution Chanel USD Million (2013-2018)
  • Table 94. Netherlands Rheumatology Therapeutics, by Route of Administration USD Million (2013-2018)
  • Table 95. Netherlands Rheumatology Therapeutics, by Disease USD Million (2013-2018)
  • Table 96. Rest of Europe Rheumatology Therapeutics, by Type USD Million (2013-2018)
  • Table 97. Rest of Europe Rheumatology Therapeutics, by Distribution Chanel USD Million (2013-2018)
  • Table 98. Rest of Europe Rheumatology Therapeutics, by Route of Administration USD Million (2013-2018)
  • Table 99. Rest of Europe Rheumatology Therapeutics, by Disease USD Million (2013-2018)
  • Table 100. MEA Rheumatology Therapeutics, by Country USD Million (2013-2018)
  • Table 101. MEA Rheumatology Therapeutics, by Type USD Million (2013-2018)
  • Table 102. MEA Rheumatology Therapeutics, by Distribution Chanel USD Million (2013-2018)
  • Table 103. MEA Rheumatology Therapeutics, by Route of Administration USD Million (2013-2018)
  • Table 104. MEA Rheumatology Therapeutics, by Disease USD Million (2013-2018)
  • Table 105. Middle East Rheumatology Therapeutics, by Type USD Million (2013-2018)
  • Table 106. Middle East Rheumatology Therapeutics, by Distribution Chanel USD Million (2013-2018)
  • Table 107. Middle East Rheumatology Therapeutics, by Route of Administration USD Million (2013-2018)
  • Table 108. Middle East Rheumatology Therapeutics, by Disease USD Million (2013-2018)
  • Table 109. Africa Rheumatology Therapeutics, by Type USD Million (2013-2018)
  • Table 110. Africa Rheumatology Therapeutics, by Distribution Chanel USD Million (2013-2018)
  • Table 111. Africa Rheumatology Therapeutics, by Route of Administration USD Million (2013-2018)
  • Table 112. Africa Rheumatology Therapeutics, by Disease USD Million (2013-2018)
  • Table 113. North America Rheumatology Therapeutics, by Country USD Million (2013-2018)
  • Table 114. North America Rheumatology Therapeutics, by Type USD Million (2013-2018)
  • Table 115. North America Rheumatology Therapeutics, by Distribution Chanel USD Million (2013-2018)
  • Table 116. North America Rheumatology Therapeutics, by Route of Administration USD Million (2013-2018)
  • Table 117. North America Rheumatology Therapeutics, by Disease USD Million (2013-2018)
  • Table 118. United States Rheumatology Therapeutics, by Type USD Million (2013-2018)
  • Table 119. United States Rheumatology Therapeutics, by Distribution Chanel USD Million (2013-2018)
  • Table 120. United States Rheumatology Therapeutics, by Route of Administration USD Million (2013-2018)
  • Table 121. United States Rheumatology Therapeutics, by Disease USD Million (2013-2018)
  • Table 122. Canada Rheumatology Therapeutics, by Type USD Million (2013-2018)
  • Table 123. Canada Rheumatology Therapeutics, by Distribution Chanel USD Million (2013-2018)
  • Table 124. Canada Rheumatology Therapeutics, by Route of Administration USD Million (2013-2018)
  • Table 125. Canada Rheumatology Therapeutics, by Disease USD Million (2013-2018)
  • Table 126. Mexico Rheumatology Therapeutics, by Type USD Million (2013-2018)
  • Table 127. Mexico Rheumatology Therapeutics, by Distribution Chanel USD Million (2013-2018)
  • Table 128. Mexico Rheumatology Therapeutics, by Route of Administration USD Million (2013-2018)
  • Table 129. Mexico Rheumatology Therapeutics, by Disease USD Million (2013-2018)
  • Table 130. Rheumatology Therapeutics Sales: by Type(Units)
  • Table 131. Rheumatology Therapeutics Sales Disease Modifying Anti-rheumatic Drugs (DMARDs) , by Region Units (2013-2018)
  • Table 132. Rheumatology Therapeutics Sales Nonsteroidal Anti-inflammatory Drugs (NSAIDs) , by Region Units (2013-2018)
  • Table 133. Rheumatology Therapeutics Sales Corticosteroids , by Region Units (2013-2018)
  • Table 134. Rheumatology Therapeutics Sales Uric Acid Drugs , by Region Units (2013-2018)
  • Table 135. Rheumatology Therapeutics Sales: by Distribution Chanel(Units)
  • Table 136. Rheumatology Therapeutics Sales Hospital Pharmacy , by Region Units (2013-2018)
  • Table 137. Rheumatology Therapeutics Sales Retail Pharmacy , by Region Units (2013-2018)
  • Table 138. Rheumatology Therapeutics Sales Online Pharmacy , by Region Units (2013-2018)
  • Table 139. Rheumatology Therapeutics Sales: by Route of Administration(Units)
  • Table 140. Rheumatology Therapeutics Sales Parenteral Route , by Region Units (2013-2018)
  • Table 141. Rheumatology Therapeutics Sales Oral Route , by Region Units (2013-2018)
  • Table 142. Rheumatology Therapeutics Sales Topical , by Region Units (2013-2018)
  • Table 143. Rheumatology Therapeutics Sales: by Disease(Units)
  • Table 144. Rheumatology Therapeutics Sales Rheumatoid Arthritis , by Region Units (2013-2018)
  • Table 145. Rheumatology Therapeutics Sales Osteoarthritis , by Region Units (2013-2018)
  • Table 146. Rheumatology Therapeutics Sales Gout , by Region Units (2013-2018)
  • Table 147. Rheumatology Therapeutics Sales Psoriatic Arthritis , by Region Units (2013-2018)
  • Table 148. Rheumatology Therapeutics Sales Ankylosing Spondylitis , by Region Units (2013-2018)
  • Table 149. Rheumatology Therapeutics Sales Other , by Region Units (2013-2018)
  • Table 150. South America Rheumatology Therapeutics Sales, by Country Units (2013-2018)
  • Table 151. South America Rheumatology Therapeutics Sales, by Type Units (2013-2018)
  • Table 152. South America Rheumatology Therapeutics Sales, by Distribution Chanel Units (2013-2018)
  • Table 153. South America Rheumatology Therapeutics Sales, by Route of Administration Units (2013-2018)
  • Table 154. South America Rheumatology Therapeutics Sales, by Disease Units (2013-2018)
  • Table 155. Brazil Rheumatology Therapeutics Sales, by Type Units (2013-2018)
  • Table 156. Brazil Rheumatology Therapeutics Sales, by Distribution Chanel Units (2013-2018)
  • Table 157. Brazil Rheumatology Therapeutics Sales, by Route of Administration Units (2013-2018)
  • Table 158. Brazil Rheumatology Therapeutics Sales, by Disease Units (2013-2018)
  • Table 159. Argentina Rheumatology Therapeutics Sales, by Type Units (2013-2018)
  • Table 160. Argentina Rheumatology Therapeutics Sales, by Distribution Chanel Units (2013-2018)
  • Table 161. Argentina Rheumatology Therapeutics Sales, by Route of Administration Units (2013-2018)
  • Table 162. Argentina Rheumatology Therapeutics Sales, by Disease Units (2013-2018)
  • Table 163. Rest of South America Rheumatology Therapeutics Sales, by Type Units (2013-2018)
  • Table 164. Rest of South America Rheumatology Therapeutics Sales, by Distribution Chanel Units (2013-2018)
  • Table 165. Rest of South America Rheumatology Therapeutics Sales, by Route of Administration Units (2013-2018)
  • Table 166. Rest of South America Rheumatology Therapeutics Sales, by Disease Units (2013-2018)
  • Table 167. Asia Pacific Rheumatology Therapeutics Sales, by Country Units (2013-2018)
  • Table 168. Asia Pacific Rheumatology Therapeutics Sales, by Type Units (2013-2018)
  • Table 169. Asia Pacific Rheumatology Therapeutics Sales, by Distribution Chanel Units (2013-2018)
  • Table 170. Asia Pacific Rheumatology Therapeutics Sales, by Route of Administration Units (2013-2018)
  • Table 171. Asia Pacific Rheumatology Therapeutics Sales, by Disease Units (2013-2018)
  • Table 172. China Rheumatology Therapeutics Sales, by Type Units (2013-2018)
  • Table 173. China Rheumatology Therapeutics Sales, by Distribution Chanel Units (2013-2018)
  • Table 174. China Rheumatology Therapeutics Sales, by Route of Administration Units (2013-2018)
  • Table 175. China Rheumatology Therapeutics Sales, by Disease Units (2013-2018)
  • Table 176. Japan Rheumatology Therapeutics Sales, by Type Units (2013-2018)
  • Table 177. Japan Rheumatology Therapeutics Sales, by Distribution Chanel Units (2013-2018)
  • Table 178. Japan Rheumatology Therapeutics Sales, by Route of Administration Units (2013-2018)
  • Table 179. Japan Rheumatology Therapeutics Sales, by Disease Units (2013-2018)
  • Table 180. India Rheumatology Therapeutics Sales, by Type Units (2013-2018)
  • Table 181. India Rheumatology Therapeutics Sales, by Distribution Chanel Units (2013-2018)
  • Table 182. India Rheumatology Therapeutics Sales, by Route of Administration Units (2013-2018)
  • Table 183. India Rheumatology Therapeutics Sales, by Disease Units (2013-2018)
  • Table 184. South Korea Rheumatology Therapeutics Sales, by Type Units (2013-2018)
  • Table 185. South Korea Rheumatology Therapeutics Sales, by Distribution Chanel Units (2013-2018)
  • Table 186. South Korea Rheumatology Therapeutics Sales, by Route of Administration Units (2013-2018)
  • Table 187. South Korea Rheumatology Therapeutics Sales, by Disease Units (2013-2018)
  • Table 188. Taiwan Rheumatology Therapeutics Sales, by Type Units (2013-2018)
  • Table 189. Taiwan Rheumatology Therapeutics Sales, by Distribution Chanel Units (2013-2018)
  • Table 190. Taiwan Rheumatology Therapeutics Sales, by Route of Administration Units (2013-2018)
  • Table 191. Taiwan Rheumatology Therapeutics Sales, by Disease Units (2013-2018)
  • Table 192. Australia Rheumatology Therapeutics Sales, by Type Units (2013-2018)
  • Table 193. Australia Rheumatology Therapeutics Sales, by Distribution Chanel Units (2013-2018)
  • Table 194. Australia Rheumatology Therapeutics Sales, by Route of Administration Units (2013-2018)
  • Table 195. Australia Rheumatology Therapeutics Sales, by Disease Units (2013-2018)
  • Table 196. Rest of Asia-Pacific Rheumatology Therapeutics Sales, by Type Units (2013-2018)
  • Table 197. Rest of Asia-Pacific Rheumatology Therapeutics Sales, by Distribution Chanel Units (2013-2018)
  • Table 198. Rest of Asia-Pacific Rheumatology Therapeutics Sales, by Route of Administration Units (2013-2018)
  • Table 199. Rest of Asia-Pacific Rheumatology Therapeutics Sales, by Disease Units (2013-2018)
  • Table 200. Europe Rheumatology Therapeutics Sales, by Country Units (2013-2018)
  • Table 201. Europe Rheumatology Therapeutics Sales, by Type Units (2013-2018)
  • Table 202. Europe Rheumatology Therapeutics Sales, by Distribution Chanel Units (2013-2018)
  • Table 203. Europe Rheumatology Therapeutics Sales, by Route of Administration Units (2013-2018)
  • Table 204. Europe Rheumatology Therapeutics Sales, by Disease Units (2013-2018)
  • Table 205. Germany Rheumatology Therapeutics Sales, by Type Units (2013-2018)
  • Table 206. Germany Rheumatology Therapeutics Sales, by Distribution Chanel Units (2013-2018)
  • Table 207. Germany Rheumatology Therapeutics Sales, by Route of Administration Units (2013-2018)
  • Table 208. Germany Rheumatology Therapeutics Sales, by Disease Units (2013-2018)
  • Table 209. France Rheumatology Therapeutics Sales, by Type Units (2013-2018)
  • Table 210. France Rheumatology Therapeutics Sales, by Distribution Chanel Units (2013-2018)
  • Table 211. France Rheumatology Therapeutics Sales, by Route of Administration Units (2013-2018)
  • Table 212. France Rheumatology Therapeutics Sales, by Disease Units (2013-2018)
  • Table 213. Italy Rheumatology Therapeutics Sales, by Type Units (2013-2018)
  • Table 214. Italy Rheumatology Therapeutics Sales, by Distribution Chanel Units (2013-2018)
  • Table 215. Italy Rheumatology Therapeutics Sales, by Route of Administration Units (2013-2018)
  • Table 216. Italy Rheumatology Therapeutics Sales, by Disease Units (2013-2018)
  • Table 217. United Kingdom Rheumatology Therapeutics Sales, by Type Units (2013-2018)
  • Table 218. United Kingdom Rheumatology Therapeutics Sales, by Distribution Chanel Units (2013-2018)
  • Table 219. United Kingdom Rheumatology Therapeutics Sales, by Route of Administration Units (2013-2018)
  • Table 220. United Kingdom Rheumatology Therapeutics Sales, by Disease Units (2013-2018)
  • Table 221. Netherlands Rheumatology Therapeutics Sales, by Type Units (2013-2018)
  • Table 222. Netherlands Rheumatology Therapeutics Sales, by Distribution Chanel Units (2013-2018)
  • Table 223. Netherlands Rheumatology Therapeutics Sales, by Route of Administration Units (2013-2018)
  • Table 224. Netherlands Rheumatology Therapeutics Sales, by Disease Units (2013-2018)
  • Table 225. Rest of Europe Rheumatology Therapeutics Sales, by Type Units (2013-2018)
  • Table 226. Rest of Europe Rheumatology Therapeutics Sales, by Distribution Chanel Units (2013-2018)
  • Table 227. Rest of Europe Rheumatology Therapeutics Sales, by Route of Administration Units (2013-2018)
  • Table 228. Rest of Europe Rheumatology Therapeutics Sales, by Disease Units (2013-2018)
  • Table 229. MEA Rheumatology Therapeutics Sales, by Country Units (2013-2018)
  • Table 230. MEA Rheumatology Therapeutics Sales, by Type Units (2013-2018)
  • Table 231. MEA Rheumatology Therapeutics Sales, by Distribution Chanel Units (2013-2018)
  • Table 232. MEA Rheumatology Therapeutics Sales, by Route of Administration Units (2013-2018)
  • Table 233. MEA Rheumatology Therapeutics Sales, by Disease Units (2013-2018)
  • Table 234. Middle East Rheumatology Therapeutics Sales, by Type Units (2013-2018)
  • Table 235. Middle East Rheumatology Therapeutics Sales, by Distribution Chanel Units (2013-2018)
  • Table 236. Middle East Rheumatology Therapeutics Sales, by Route of Administration Units (2013-2018)
  • Table 237. Middle East Rheumatology Therapeutics Sales, by Disease Units (2013-2018)
  • Table 238. Africa Rheumatology Therapeutics Sales, by Type Units (2013-2018)
  • Table 239. Africa Rheumatology Therapeutics Sales, by Distribution Chanel Units (2013-2018)
  • Table 240. Africa Rheumatology Therapeutics Sales, by Route of Administration Units (2013-2018)
  • Table 241. Africa Rheumatology Therapeutics Sales, by Disease Units (2013-2018)
  • Table 242. North America Rheumatology Therapeutics Sales, by Country Units (2013-2018)
  • Table 243. North America Rheumatology Therapeutics Sales, by Type Units (2013-2018)
  • Table 244. North America Rheumatology Therapeutics Sales, by Distribution Chanel Units (2013-2018)
  • Table 245. North America Rheumatology Therapeutics Sales, by Route of Administration Units (2013-2018)
  • Table 246. North America Rheumatology Therapeutics Sales, by Disease Units (2013-2018)
  • Table 247. United States Rheumatology Therapeutics Sales, by Type Units (2013-2018)
  • Table 248. United States Rheumatology Therapeutics Sales, by Distribution Chanel Units (2013-2018)
  • Table 249. United States Rheumatology Therapeutics Sales, by Route of Administration Units (2013-2018)
  • Table 250. United States Rheumatology Therapeutics Sales, by Disease Units (2013-2018)
  • Table 251. Canada Rheumatology Therapeutics Sales, by Type Units (2013-2018)
  • Table 252. Canada Rheumatology Therapeutics Sales, by Distribution Chanel Units (2013-2018)
  • Table 253. Canada Rheumatology Therapeutics Sales, by Route of Administration Units (2013-2018)
  • Table 254. Canada Rheumatology Therapeutics Sales, by Disease Units (2013-2018)
  • Table 255. Mexico Rheumatology Therapeutics Sales, by Type Units (2013-2018)
  • Table 256. Mexico Rheumatology Therapeutics Sales, by Distribution Chanel Units (2013-2018)
  • Table 257. Mexico Rheumatology Therapeutics Sales, by Route of Administration Units (2013-2018)
  • Table 258. Mexico Rheumatology Therapeutics Sales, by Disease Units (2013-2018)
  • Table 259. Rheumatology Therapeutics: by Type(USD/Units)
  • Table 260. Company Basic Information, Sales Area and Its Competitors
  • Table 261. Company Basic Information, Sales Area and Its Competitors
  • Table 262. Company Basic Information, Sales Area and Its Competitors
  • Table 263. Company Basic Information, Sales Area and Its Competitors
  • Table 264. Company Basic Information, Sales Area and Its Competitors
  • Table 265. Company Basic Information, Sales Area and Its Competitors
  • Table 266. Company Basic Information, Sales Area and Its Competitors
  • Table 267. Company Basic Information, Sales Area and Its Competitors
  • Table 268. Company Basic Information, Sales Area and Its Competitors
  • Table 269. Company Basic Information, Sales Area and Its Competitors
  • Table 270. Rheumatology Therapeutics: by Type(USD Million)
  • Table 271. Rheumatology Therapeutics Disease Modifying Anti-rheumatic Drugs (DMARDs) , by Region USD Million (2019-2024)
  • Table 272. Rheumatology Therapeutics Nonsteroidal Anti-inflammatory Drugs (NSAIDs) , by Region USD Million (2019-2024)
  • Table 273. Rheumatology Therapeutics Corticosteroids , by Region USD Million (2019-2024)
  • Table 274. Rheumatology Therapeutics Uric Acid Drugs , by Region USD Million (2019-2024)
  • Table 275. Rheumatology Therapeutics: by Distribution Chanel(USD Million)
  • Table 276. Rheumatology Therapeutics Hospital Pharmacy , by Region USD Million (2019-2024)
  • Table 277. Rheumatology Therapeutics Retail Pharmacy , by Region USD Million (2019-2024)
  • Table 278. Rheumatology Therapeutics Online Pharmacy , by Region USD Million (2019-2024)
  • Table 279. Rheumatology Therapeutics: by Route of Administration(USD Million)
  • Table 280. Rheumatology Therapeutics Parenteral Route , by Region USD Million (2019-2024)
  • Table 281. Rheumatology Therapeutics Oral Route , by Region USD Million (2019-2024)
  • Table 282. Rheumatology Therapeutics Topical , by Region USD Million (2019-2024)
  • Table 283. Rheumatology Therapeutics: by Disease(USD Million)
  • Table 284. Rheumatology Therapeutics Rheumatoid Arthritis , by Region USD Million (2019-2024)
  • Table 285. Rheumatology Therapeutics Osteoarthritis , by Region USD Million (2019-2024)
  • Table 286. Rheumatology Therapeutics Gout , by Region USD Million (2019-2024)
  • Table 287. Rheumatology Therapeutics Psoriatic Arthritis , by Region USD Million (2019-2024)
  • Table 288. Rheumatology Therapeutics Ankylosing Spondylitis , by Region USD Million (2019-2024)
  • Table 289. Rheumatology Therapeutics Other , by Region USD Million (2019-2024)
  • Table 290. South America Rheumatology Therapeutics, by Country USD Million (2019-2024)
  • Table 291. South America Rheumatology Therapeutics, by Type USD Million (2019-2024)
  • Table 292. South America Rheumatology Therapeutics, by Distribution Chanel USD Million (2019-2024)
  • Table 293. South America Rheumatology Therapeutics, by Route of Administration USD Million (2019-2024)
  • Table 294. South America Rheumatology Therapeutics, by Disease USD Million (2019-2024)
  • Table 295. Brazil Rheumatology Therapeutics, by Type USD Million (2019-2024)
  • Table 296. Brazil Rheumatology Therapeutics, by Distribution Chanel USD Million (2019-2024)
  • Table 297. Brazil Rheumatology Therapeutics, by Route of Administration USD Million (2019-2024)
  • Table 298. Brazil Rheumatology Therapeutics, by Disease USD Million (2019-2024)
  • Table 299. Argentina Rheumatology Therapeutics, by Type USD Million (2019-2024)
  • Table 300. Argentina Rheumatology Therapeutics, by Distribution Chanel USD Million (2019-2024)
  • Table 301. Argentina Rheumatology Therapeutics, by Route of Administration USD Million (2019-2024)
  • Table 302. Argentina Rheumatology Therapeutics, by Disease USD Million (2019-2024)
  • Table 303. Rest of South America Rheumatology Therapeutics, by Type USD Million (2019-2024)
  • Table 304. Rest of South America Rheumatology Therapeutics, by Distribution Chanel USD Million (2019-2024)
  • Table 305. Rest of South America Rheumatology Therapeutics, by Route of Administration USD Million (2019-2024)
  • Table 306. Rest of South America Rheumatology Therapeutics, by Disease USD Million (2019-2024)
  • Table 307. Asia Pacific Rheumatology Therapeutics, by Country USD Million (2019-2024)
  • Table 308. Asia Pacific Rheumatology Therapeutics, by Type USD Million (2019-2024)
  • Table 309. Asia Pacific Rheumatology Therapeutics, by Distribution Chanel USD Million (2019-2024)
  • Table 310. Asia Pacific Rheumatology Therapeutics, by Route of Administration USD Million (2019-2024)
  • Table 311. Asia Pacific Rheumatology Therapeutics, by Disease USD Million (2019-2024)
  • Table 312. China Rheumatology Therapeutics, by Type USD Million (2019-2024)
  • Table 313. China Rheumatology Therapeutics, by Distribution Chanel USD Million (2019-2024)
  • Table 314. China Rheumatology Therapeutics, by Route of Administration USD Million (2019-2024)
  • Table 315. China Rheumatology Therapeutics, by Disease USD Million (2019-2024)
  • Table 316. Japan Rheumatology Therapeutics, by Type USD Million (2019-2024)
  • Table 317. Japan Rheumatology Therapeutics, by Distribution Chanel USD Million (2019-2024)
  • Table 318. Japan Rheumatology Therapeutics, by Route of Administration USD Million (2019-2024)
  • Table 319. Japan Rheumatology Therapeutics, by Disease USD Million (2019-2024)
  • Table 320. India Rheumatology Therapeutics, by Type USD Million (2019-2024)
  • Table 321. India Rheumatology Therapeutics, by Distribution Chanel USD Million (2019-2024)
  • Table 322. India Rheumatology Therapeutics, by Route of Administration USD Million (2019-2024)
  • Table 323. India Rheumatology Therapeutics, by Disease USD Million (2019-2024)
  • Table 324. South Korea Rheumatology Therapeutics, by Type USD Million (2019-2024)
  • Table 325. South Korea Rheumatology Therapeutics, by Distribution Chanel USD Million (2019-2024)
  • Table 326. South Korea Rheumatology Therapeutics, by Route of Administration USD Million (2019-2024)
  • Table 327. South Korea Rheumatology Therapeutics, by Disease USD Million (2019-2024)
  • Table 328. Taiwan Rheumatology Therapeutics, by Type USD Million (2019-2024)
  • Table 329. Taiwan Rheumatology Therapeutics, by Distribution Chanel USD Million (2019-2024)
  • Table 330. Taiwan Rheumatology Therapeutics, by Route of Administration USD Million (2019-2024)
  • Table 331. Taiwan Rheumatology Therapeutics, by Disease USD Million (2019-2024)
  • Table 332. Australia Rheumatology Therapeutics, by Type USD Million (2019-2024)
  • Table 333. Australia Rheumatology Therapeutics, by Distribution Chanel USD Million (2019-2024)
  • Table 334. Australia Rheumatology Therapeutics, by Route of Administration USD Million (2019-2024)
  • Table 335. Australia Rheumatology Therapeutics, by Disease USD Million (2019-2024)
  • Table 336. Rest of Asia-Pacific Rheumatology Therapeutics, by Type USD Million (2019-2024)
  • Table 337. Rest of Asia-Pacific Rheumatology Therapeutics, by Distribution Chanel USD Million (2019-2024)
  • Table 338. Rest of Asia-Pacific Rheumatology Therapeutics, by Route of Administration USD Million (2019-2024)
  • Table 339. Rest of Asia-Pacific Rheumatology Therapeutics, by Disease USD Million (2019-2024)
  • Table 340. Europe Rheumatology Therapeutics, by Country USD Million (2019-2024)
  • Table 341. Europe Rheumatology Therapeutics, by Type USD Million (2019-2024)
  • Table 342. Europe Rheumatology Therapeutics, by Distribution Chanel USD Million (2019-2024)
  • Table 343. Europe Rheumatology Therapeutics, by Route of Administration USD Million (2019-2024)
  • Table 344. Europe Rheumatology Therapeutics, by Disease USD Million (2019-2024)
  • Table 345. Germany Rheumatology Therapeutics, by Type USD Million (2019-2024)
  • Table 346. Germany Rheumatology Therapeutics, by Distribution Chanel USD Million (2019-2024)
  • Table 347. Germany Rheumatology Therapeutics, by Route of Administration USD Million (2019-2024)
  • Table 348. Germany Rheumatology Therapeutics, by Disease USD Million (2019-2024)
  • Table 349. France Rheumatology Therapeutics, by Type USD Million (2019-2024)
  • Table 350. France Rheumatology Therapeutics, by Distribution Chanel USD Million (2019-2024)
  • Table 351. France Rheumatology Therapeutics, by Route of Administration USD Million (2019-2024)
  • Table 352. France Rheumatology Therapeutics, by Disease USD Million (2019-2024)
  • Table 353. Italy Rheumatology Therapeutics, by Type USD Million (2019-2024)
  • Table 354. Italy Rheumatology Therapeutics, by Distribution Chanel USD Million (2019-2024)
  • Table 355. Italy Rheumatology Therapeutics, by Route of Administration USD Million (2019-2024)
  • Table 356. Italy Rheumatology Therapeutics, by Disease USD Million (2019-2024)
  • Table 357. United Kingdom Rheumatology Therapeutics, by Type USD Million (2019-2024)
  • Table 358. United Kingdom Rheumatology Therapeutics, by Distribution Chanel USD Million (2019-2024)
  • Table 359. United Kingdom Rheumatology Therapeutics, by Route of Administration USD Million (2019-2024)
  • Table 360. United Kingdom Rheumatology Therapeutics, by Disease USD Million (2019-2024)
  • Table 361. Netherlands Rheumatology Therapeutics, by Type USD Million (2019-2024)
  • Table 362. Netherlands Rheumatology Therapeutics, by Distribution Chanel USD Million (2019-2024)
  • Table 363. Netherlands Rheumatology Therapeutics, by Route of Administration USD Million (2019-2024)
  • Table 364. Netherlands Rheumatology Therapeutics, by Disease USD Million (2019-2024)
  • Table 365. Rest of Europe Rheumatology Therapeutics, by Type USD Million (2019-2024)
  • Table 366. Rest of Europe Rheumatology Therapeutics, by Distribution Chanel USD Million (2019-2024)
  • Table 367. Rest of Europe Rheumatology Therapeutics, by Route of Administration USD Million (2019-2024)
  • Table 368. Rest of Europe Rheumatology Therapeutics, by Disease USD Million (2019-2024)
  • Table 369. MEA Rheumatology Therapeutics, by Country USD Million (2019-2024)
  • Table 370. MEA Rheumatology Therapeutics, by Type USD Million (2019-2024)
  • Table 371. MEA Rheumatology Therapeutics, by Distribution Chanel USD Million (2019-2024)
  • Table 372. MEA Rheumatology Therapeutics, by Route of Administration USD Million (2019-2024)
  • Table 373. MEA Rheumatology Therapeutics, by Disease USD Million (2019-2024)
  • Table 374. Middle East Rheumatology Therapeutics, by Type USD Million (2019-2024)
  • Table 375. Middle East Rheumatology Therapeutics, by Distribution Chanel USD Million (2019-2024)
  • Table 376. Middle East Rheumatology Therapeutics, by Route of Administration USD Million (2019-2024)
  • Table 377. Middle East Rheumatology Therapeutics, by Disease USD Million (2019-2024)
  • Table 378. Africa Rheumatology Therapeutics, by Type USD Million (2019-2024)
  • Table 379. Africa Rheumatology Therapeutics, by Distribution Chanel USD Million (2019-2024)
  • Table 380. Africa Rheumatology Therapeutics, by Route of Administration USD Million (2019-2024)
  • Table 381. Africa Rheumatology Therapeutics, by Disease USD Million (2019-2024)
  • Table 382. North America Rheumatology Therapeutics, by Country USD Million (2019-2024)
  • Table 383. North America Rheumatology Therapeutics, by Type USD Million (2019-2024)
  • Table 384. North America Rheumatology Therapeutics, by Distribution Chanel USD Million (2019-2024)
  • Table 385. North America Rheumatology Therapeutics, by Route of Administration USD Million (2019-2024)
  • Table 386. North America Rheumatology Therapeutics, by Disease USD Million (2019-2024)
  • Table 387. United States Rheumatology Therapeutics, by Type USD Million (2019-2024)
  • Table 388. United States Rheumatology Therapeutics, by Distribution Chanel USD Million (2019-2024)
  • Table 389. United States Rheumatology Therapeutics, by Route of Administration USD Million (2019-2024)
  • Table 390. United States Rheumatology Therapeutics, by Disease USD Million (2019-2024)
  • Table 391. Canada Rheumatology Therapeutics, by Type USD Million (2019-2024)
  • Table 392. Canada Rheumatology Therapeutics, by Distribution Chanel USD Million (2019-2024)
  • Table 393. Canada Rheumatology Therapeutics, by Route of Administration USD Million (2019-2024)
  • Table 394. Canada Rheumatology Therapeutics, by Disease USD Million (2019-2024)
  • Table 395. Mexico Rheumatology Therapeutics, by Type USD Million (2019-2024)
  • Table 396. Mexico Rheumatology Therapeutics, by Distribution Chanel USD Million (2019-2024)
  • Table 397. Mexico Rheumatology Therapeutics, by Route of Administration USD Million (2019-2024)
  • Table 398. Mexico Rheumatology Therapeutics, by Disease USD Million (2019-2024)
  • Table 399. Rheumatology Therapeutics Sales: by Type(Units)
  • Table 400. Rheumatology Therapeutics Sales Disease Modifying Anti-rheumatic Drugs (DMARDs) , by Region Units (2019-2024)
  • Table 401. Rheumatology Therapeutics Sales Nonsteroidal Anti-inflammatory Drugs (NSAIDs) , by Region Units (2019-2024)
  • Table 402. Rheumatology Therapeutics Sales Corticosteroids , by Region Units (2019-2024)
  • Table 403. Rheumatology Therapeutics Sales Uric Acid Drugs , by Region Units (2019-2024)
  • Table 404. Rheumatology Therapeutics Sales: by Distribution Chanel(Units)
  • Table 405. Rheumatology Therapeutics Sales Hospital Pharmacy , by Region Units (2019-2024)
  • Table 406. Rheumatology Therapeutics Sales Retail Pharmacy , by Region Units (2019-2024)
  • Table 407. Rheumatology Therapeutics Sales Online Pharmacy , by Region Units (2019-2024)
  • Table 408. Rheumatology Therapeutics Sales: by Route of Administration(Units)
  • Table 409. Rheumatology Therapeutics Sales Parenteral Route , by Region Units (2019-2024)
  • Table 410. Rheumatology Therapeutics Sales Oral Route , by Region Units (2019-2024)
  • Table 411. Rheumatology Therapeutics Sales Topical , by Region Units (2019-2024)
  • Table 412. Rheumatology Therapeutics Sales: by Disease(Units)
  • Table 413. Rheumatology Therapeutics Sales Rheumatoid Arthritis , by Region Units (2019-2024)
  • Table 414. Rheumatology Therapeutics Sales Osteoarthritis , by Region Units (2019-2024)
  • Table 415. Rheumatology Therapeutics Sales Gout , by Region Units (2019-2024)
  • Table 416. Rheumatology Therapeutics Sales Psoriatic Arthritis , by Region Units (2019-2024)
  • Table 417. Rheumatology Therapeutics Sales Ankylosing Spondylitis , by Region Units (2019-2024)
  • Table 418. Rheumatology Therapeutics Sales Other , by Region Units (2019-2024)
  • Table 419. South America Rheumatology Therapeutics Sales, by Country Units (2019-2024)
  • Table 420. South America Rheumatology Therapeutics Sales, by Type Units (2019-2024)
  • Table 421. South America Rheumatology Therapeutics Sales, by Distribution Chanel Units (2019-2024)
  • Table 422. South America Rheumatology Therapeutics Sales, by Route of Administration Units (2019-2024)
  • Table 423. South America Rheumatology Therapeutics Sales, by Disease Units (2019-2024)
  • Table 424. Brazil Rheumatology Therapeutics Sales, by Type Units (2019-2024)
  • Table 425. Brazil Rheumatology Therapeutics Sales, by Distribution Chanel Units (2019-2024)
  • Table 426. Brazil Rheumatology Therapeutics Sales, by Route of Administration Units (2019-2024)
  • Table 427. Brazil Rheumatology Therapeutics Sales, by Disease Units (2019-2024)
  • Table 428. Argentina Rheumatology Therapeutics Sales, by Type Units (2019-2024)
  • Table 429. Argentina Rheumatology Therapeutics Sales, by Distribution Chanel Units (2019-2024)
  • Table 430. Argentina Rheumatology Therapeutics Sales, by Route of Administration Units (2019-2024)
  • Table 431. Argentina Rheumatology Therapeutics Sales, by Disease Units (2019-2024)
  • Table 432. Rest of South America Rheumatology Therapeutics Sales, by Type Units (2019-2024)
  • Table 433. Rest of South America Rheumatology Therapeutics Sales, by Distribution Chanel Units (2019-2024)
  • Table 434. Rest of South America Rheumatology Therapeutics Sales, by Route of Administration Units (2019-2024)
  • Table 435. Rest of South America Rheumatology Therapeutics Sales, by Disease Units (2019-2024)
  • Table 436. Asia Pacific Rheumatology Therapeutics Sales, by Country Units (2019-2024)
  • Table 437. Asia Pacific Rheumatology Therapeutics Sales, by Type Units (2019-2024)
  • Table 438. Asia Pacific Rheumatology Therapeutics Sales, by Distribution Chanel Units (2019-2024)
  • Table 439. Asia Pacific Rheumatology Therapeutics Sales, by Route of Administration Units (2019-2024)
  • Table 440. Asia Pacific Rheumatology Therapeutics Sales, by Disease Units (2019-2024)
  • Table 441. China Rheumatology Therapeutics Sales, by Type Units (2019-2024)
  • Table 442. China Rheumatology Therapeutics Sales, by Distribution Chanel Units (2019-2024)
  • Table 443. China Rheumatology Therapeutics Sales, by Route of Administration Units (2019-2024)
  • Table 444. China Rheumatology Therapeutics Sales, by Disease Units (2019-2024)
  • Table 445. Japan Rheumatology Therapeutics Sales, by Type Units (2019-2024)
  • Table 446. Japan Rheumatology Therapeutics Sales, by Distribution Chanel Units (2019-2024)
  • Table 447. Japan Rheumatology Therapeutics Sales, by Route of Administration Units (2019-2024)
  • Table 448. Japan Rheumatology Therapeutics Sales, by Disease Units (2019-2024)
  • Table 449. India Rheumatology Therapeutics Sales, by Type Units (2019-2024)
  • Table 450. India Rheumatology Therapeutics Sales, by Distribution Chanel Units (2019-2024)
  • Table 451. India Rheumatology Therapeutics Sales, by Route of Administration Units (2019-2024)
  • Table 452. India Rheumatology Therapeutics Sales, by Disease Units (2019-2024)
  • Table 453. South Korea Rheumatology Therapeutics Sales, by Type Units (2019-2024)
  • Table 454. South Korea Rheumatology Therapeutics Sales, by Distribution Chanel Units (2019-2024)
  • Table 455. South Korea Rheumatology Therapeutics Sales, by Route of Administration Units (2019-2024)
  • Table 456. South Korea Rheumatology Therapeutics Sales, by Disease Units (2019-2024)
  • Table 457. Taiwan Rheumatology Therapeutics Sales, by Type Units (2019-2024)
  • Table 458. Taiwan Rheumatology Therapeutics Sales, by Distribution Chanel Units (2019-2024)
  • Table 459. Taiwan Rheumatology Therapeutics Sales, by Route of Administration Units (2019-2024)
  • Table 460. Taiwan Rheumatology Therapeutics Sales, by Disease Units (2019-2024)
  • Table 461. Australia Rheumatology Therapeutics Sales, by Type Units (2019-2024)
  • Table 462. Australia Rheumatology Therapeutics Sales, by Distribution Chanel Units (2019-2024)
  • Table 463. Australia Rheumatology Therapeutics Sales, by Route of Administration Units (2019-2024)
  • Table 464. Australia Rheumatology Therapeutics Sales, by Disease Units (2019-2024)
  • Table 465. Rest of Asia-Pacific Rheumatology Therapeutics Sales, by Type Units (2019-2024)
  • Table 466. Rest of Asia-Pacific Rheumatology Therapeutics Sales, by Distribution Chanel Units (2019-2024)
  • Table 467. Rest of Asia-Pacific Rheumatology Therapeutics Sales, by Route of Administration Units (2019-2024)
  • Table 468. Rest of Asia-Pacific Rheumatology Therapeutics Sales, by Disease Units (2019-2024)
  • Table 469. Europe Rheumatology Therapeutics Sales, by Country Units (2019-2024)
  • Table 470. Europe Rheumatology Therapeutics Sales, by Type Units (2019-2024)
  • Table 471. Europe Rheumatology Therapeutics Sales, by Distribution Chanel Units (2019-2024)
  • Table 472. Europe Rheumatology Therapeutics Sales, by Route of Administration Units (2019-2024)
  • Table 473. Europe Rheumatology Therapeutics Sales, by Disease Units (2019-2024)
  • Table 474. Germany Rheumatology Therapeutics Sales, by Type Units (2019-2024)
  • Table 475. Germany Rheumatology Therapeutics Sales, by Distribution Chanel Units (2019-2024)
  • Table 476. Germany Rheumatology Therapeutics Sales, by Route of Administration Units (2019-2024)
  • Table 477. Germany Rheumatology Therapeutics Sales, by Disease Units (2019-2024)
  • Table 478. France Rheumatology Therapeutics Sales, by Type Units (2019-2024)
  • Table 479. France Rheumatology Therapeutics Sales, by Distribution Chanel Units (2019-2024)
  • Table 480. France Rheumatology Therapeutics Sales, by Route of Administration Units (2019-2024)
  • Table 481. France Rheumatology Therapeutics Sales, by Disease Units (2019-2024)
  • Table 482. Italy Rheumatology Therapeutics Sales, by Type Units (2019-2024)
  • Table 483. Italy Rheumatology Therapeutics Sales, by Distribution Chanel Units (2019-2024)
  • Table 484. Italy Rheumatology Therapeutics Sales, by Route of Administration Units (2019-2024)
  • Table 485. Italy Rheumatology Therapeutics Sales, by Disease Units (2019-2024)
  • Table 486. United Kingdom Rheumatology Therapeutics Sales, by Type Units (2019-2024)
  • Table 487. United Kingdom Rheumatology Therapeutics Sales, by Distribution Chanel Units (2019-2024)
  • Table 488. United Kingdom Rheumatology Therapeutics Sales, by Route of Administration Units (2019-2024)
  • Table 489. United Kingdom Rheumatology Therapeutics Sales, by Disease Units (2019-2024)
  • Table 490. Netherlands Rheumatology Therapeutics Sales, by Type Units (2019-2024)
  • Table 491. Netherlands Rheumatology Therapeutics Sales, by Distribution Chanel Units (2019-2024)
  • Table 492. Netherlands Rheumatology Therapeutics Sales, by Route of Administration Units (2019-2024)
  • Table 493. Netherlands Rheumatology Therapeutics Sales, by Disease Units (2019-2024)
  • Table 494. Rest of Europe Rheumatology Therapeutics Sales, by Type Units (2019-2024)
  • Table 495. Rest of Europe Rheumatology Therapeutics Sales, by Distribution Chanel Units (2019-2024)
  • Table 496. Rest of Europe Rheumatology Therapeutics Sales, by Route of Administration Units (2019-2024)
  • Table 497. Rest of Europe Rheumatology Therapeutics Sales, by Disease Units (2019-2024)
  • Table 498. MEA Rheumatology Therapeutics Sales, by Country Units (2019-2024)
  • Table 499. MEA Rheumatology Therapeutics Sales, by Type Units (2019-2024)
  • Table 500. MEA Rheumatology Therapeutics Sales, by Distribution Chanel Units (2019-2024)
  • Table 501. MEA Rheumatology Therapeutics Sales, by Route of Administration Units (2019-2024)
  • Table 502. MEA Rheumatology Therapeutics Sales, by Disease Units (2019-2024)
  • Table 503. Middle East Rheumatology Therapeutics Sales, by Type Units (2019-2024)
  • Table 504. Middle East Rheumatology Therapeutics Sales, by Distribution Chanel Units (2019-2024)
  • Table 505. Middle East Rheumatology Therapeutics Sales, by Route of Administration Units (2019-2024)
  • Table 506. Middle East Rheumatology Therapeutics Sales, by Disease Units (2019-2024)
  • Table 507. Africa Rheumatology Therapeutics Sales, by Type Units (2019-2024)
  • Table 508. Africa Rheumatology Therapeutics Sales, by Distribution Chanel Units (2019-2024)
  • Table 509. Africa Rheumatology Therapeutics Sales, by Route of Administration Units (2019-2024)
  • Table 510. Africa Rheumatology Therapeutics Sales, by Disease Units (2019-2024)
  • Table 511. North America Rheumatology Therapeutics Sales, by Country Units (2019-2024)
  • Table 512. North America Rheumatology Therapeutics Sales, by Type Units (2019-2024)
  • Table 513. North America Rheumatology Therapeutics Sales, by Distribution Chanel Units (2019-2024)
  • Table 514. North America Rheumatology Therapeutics Sales, by Route of Administration Units (2019-2024)
  • Table 515. North America Rheumatology Therapeutics Sales, by Disease Units (2019-2024)
  • Table 516. United States Rheumatology Therapeutics Sales, by Type Units (2019-2024)
  • Table 517. United States Rheumatology Therapeutics Sales, by Distribution Chanel Units (2019-2024)
  • Table 518. United States Rheumatology Therapeutics Sales, by Route of Administration Units (2019-2024)
  • Table 519. United States Rheumatology Therapeutics Sales, by Disease Units (2019-2024)
  • Table 520. Canada Rheumatology Therapeutics Sales, by Type Units (2019-2024)
  • Table 521. Canada Rheumatology Therapeutics Sales, by Distribution Chanel Units (2019-2024)
  • Table 522. Canada Rheumatology Therapeutics Sales, by Route of Administration Units (2019-2024)
  • Table 523. Canada Rheumatology Therapeutics Sales, by Disease Units (2019-2024)
  • Table 524. Mexico Rheumatology Therapeutics Sales, by Type Units (2019-2024)
  • Table 525. Mexico Rheumatology Therapeutics Sales, by Distribution Chanel Units (2019-2024)
  • Table 526. Mexico Rheumatology Therapeutics Sales, by Route of Administration Units (2019-2024)
  • Table 527. Mexico Rheumatology Therapeutics Sales, by Disease Units (2019-2024)
  • Table 528. Rheumatology Therapeutics: by Type(USD/Units)
  • Table 529. Research Programs/Design for This Report
  • Table 530. Key Data Information from Secondary Sources
  • Table 531. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Rheumatology Therapeutics: by Type USD Million (2013-2018)
  • Figure 5. Global Rheumatology Therapeutics: by Distribution Chanel USD Million (2013-2018)
  • Figure 6. Global Rheumatology Therapeutics: by Route of Administration USD Million (2013-2018)
  • Figure 7. Global Rheumatology Therapeutics: by Disease USD Million (2013-2018)
  • Figure 8. South America Rheumatology Therapeutics Share (%), by Country
  • Figure 9. Asia Pacific Rheumatology Therapeutics Share (%), by Country
  • Figure 10. Europe Rheumatology Therapeutics Share (%), by Country
  • Figure 11. MEA Rheumatology Therapeutics Share (%), by Country
  • Figure 12. North America Rheumatology Therapeutics Share (%), by Country
  • Figure 13. Global Rheumatology Therapeutics: by Type Units (2013-2018)
  • Figure 14. Global Rheumatology Therapeutics: by Distribution Chanel Units (2013-2018)
  • Figure 15. Global Rheumatology Therapeutics: by Route of Administration Units (2013-2018)
  • Figure 16. Global Rheumatology Therapeutics: by Disease Units (2013-2018)
  • Figure 17. South America Rheumatology Therapeutics Share (%), by Country
  • Figure 18. Asia Pacific Rheumatology Therapeutics Share (%), by Country
  • Figure 19. Europe Rheumatology Therapeutics Share (%), by Country
  • Figure 20. MEA Rheumatology Therapeutics Share (%), by Country
  • Figure 21. North America Rheumatology Therapeutics Share (%), by Country
  • Figure 22. Global Rheumatology Therapeutics: by Type USD/Units (2013-2018)
  • Figure 23. Global Rheumatology Therapeutics share by Players 2018 (%)
  • Figure 24. Global Rheumatology Therapeutics share by Players (Top 3) 2018(%)
  • Figure 25. Global Rheumatology Therapeutics share by Players (Top 5) 2018(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. AbbVie, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. AbbVie, Inc. (United States) Revenue: by Geography 2018
  • Figure 29. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 30. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2018
  • Figure 31. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 32. Pfizer (United States) Revenue: by Geography 2018
  • Figure 33. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Merck & Co., Inc. (United States) Revenue: by Geography 2018
  • Figure 35. Amgen, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Amgen, Inc. (United States) Revenue: by Geography 2018
  • Figure 37. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 38. Novartis AG (Switzerland) Revenue: by Geography 2018
  • Figure 39. Janssen Biotech, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 40. Janssen Biotech, Inc. (United States) Revenue: by Geography 2018
  • Figure 41. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 42. Sanofi (France) Revenue: by Geography 2018
  • Figure 43. Genentech, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 44. Genentech, Inc. (United States) Revenue: by Geography 2018
  • Figure 45. Takeda Pharmaceutical (Japan) Revenue, Net Income and Gross profit
  • Figure 46. Takeda Pharmaceutical (Japan) Revenue: by Geography 2018
  • Figure 47. Global Rheumatology Therapeutics: by Type USD Million (2019-2024)
  • Figure 48. Global Rheumatology Therapeutics: by Distribution Chanel USD Million (2019-2024)
  • Figure 49. Global Rheumatology Therapeutics: by Route of Administration USD Million (2019-2024)
  • Figure 50. Global Rheumatology Therapeutics: by Disease USD Million (2019-2024)
  • Figure 51. South America Rheumatology Therapeutics Share (%), by Country
  • Figure 52. Asia Pacific Rheumatology Therapeutics Share (%), by Country
  • Figure 53. Europe Rheumatology Therapeutics Share (%), by Country
  • Figure 54. MEA Rheumatology Therapeutics Share (%), by Country
  • Figure 55. North America Rheumatology Therapeutics Share (%), by Country
  • Figure 56. Global Rheumatology Therapeutics: by Type Units (2019-2024)
  • Figure 57. Global Rheumatology Therapeutics: by Distribution Chanel Units (2019-2024)
  • Figure 58. Global Rheumatology Therapeutics: by Route of Administration Units (2019-2024)
  • Figure 59. Global Rheumatology Therapeutics: by Disease Units (2019-2024)
  • Figure 60. South America Rheumatology Therapeutics Share (%), by Country
  • Figure 61. Asia Pacific Rheumatology Therapeutics Share (%), by Country
  • Figure 62. Europe Rheumatology Therapeutics Share (%), by Country
  • Figure 63. MEA Rheumatology Therapeutics Share (%), by Country
  • Figure 64. North America Rheumatology Therapeutics Share (%), by Country
  • Figure 65. Global Rheumatology Therapeutics: by Type USD/Units (2019-2024)
Some of the key companies/manufacturers profiled in the report
  • AbbVie, Inc. (United States)
  • Bristol-Myers Squibb Company (United States)
  • Pfizer (United States)
  • Merck & Co., Inc. (United States)
  • Amgen, Inc. (United States)
  • Novartis AG (Switzerland)
  • Janssen Biotech, Inc. (United States)
  • Sanofi (France)
  • Genentech, Inc. (United States)
  • Takeda Pharmaceutical (Japan)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation